edgen-logo

AI Copilot
portfolioPortfolio

Stocks

Crypto

News
StocksCrypto

Chat History

Aura
Follow our

Join our

EN
Back

Tempus AI's PurIST® Algorithm Validated for Pancreatic Cancer Therapy Selection
Stock NewsThemesTempus AI's PurIST® Algorithm Validated for Pancreatic Cancer Therapy Selection

Tempus AI's PurIST® Algorithm Validated for Pancreatic Cancer Therapy Selection

Edgen StockEdgen Stock·Sep 13 2025, 03:25
Share to
Share to
Copy link
TEMTEM+5.29%
Tempus AI's PurIST® Algorithm Validated for Pancreatic Cancer Therapy Selection
source:
[1] Tempus Announces New Study in JCO Precision Oncology Validating PurIST® Algorithm for Enhanced Therapy Selection in Pancreatic Cancer (https://finance.yahoo.com/news/tempus-announc ...)[2] TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape | Nasdaq (https://vertexaisearch.cloud.google.com/groun ...)[3] TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape - Zacks (https://www.zacks.com/stock/news/2480000/tem- ...)

Related News

Babcock & Wilcox Secures $40M Refinery Contract
Dec 19 2025, 22:38

Babcock & Wilcox Secures $40M Refinery Contract

Babcock & Wilcox announced on December 19, 2025, that it secured a $40 million contract to supply its Wet Gas Scrubbing technology to a Canadian petroleum refinery, major Canadian petroleum refinery.

Tesla Profits Plunge 53% as Politics Cost 1.26M Sales
Dec 19 2025, 22:29

Tesla Profits Plunge 53% as Politics Cost 1.26M Sales

A Yale study finds Elon Musk's political stance cost Tesla 1.26 million car sales, contributing to a profit drop to $7.1 billion in 2024 from $15 billion in 2023.

Mizuho Lifts Tesla Target to $530 on Robotaxi Hopes
Dec 19 2025, 22:27

Mizuho Lifts Tesla Target to $530 on Robotaxi Hopes

On December 16, Mizuho increased its price target for Tesla to $530, citing growing confidence in the automaker's future robotaxi business.